AbbVie Demonstrates Leadership in HCV with New MAVYRET(TM) (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017; - 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET

Press/Media: Press / Media

PeriodOct 11 2017

Media coverage

1

Media coverage

  • TitleAbbVie Demonstrates Leadership in HCV with New MAVYRET(TM) (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017; - 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET
    Media name/outletPR Newswire
    CountryUnited States
    Date10/11/17
    PersonsFred Poordad